Celebrex Cardiovascular Safety Supported In FDA/Kaiser Study
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA releases data from COX-2 cardiovascular safety study that was included in a Sept. 30 internal memo to Office of Drug Safety Director Seligman. The study shows Celebrex patients have lower cardiovascular safety risk compared to remote NSAID users.
You may also be interested in...
FDA/Kaiser Study Revises Cardiovascular Risk For Merck's Vioxx
The study, led by FDA Office of Drug Safety official Graham, shows a 1.34 relative risk for Vioxx compared to remote NSAID use after data were revised to "correctly apply enrollment criteria for cases and controls." The study was not powered to detect an effect for Vioxx based on duration of use.
FDA/Kaiser Study Revises Cardiovascular Risk For Merck's Vioxx
The study, led by FDA Office of Drug Safety official Graham, shows a 1.34 relative risk for Vioxx compared to remote NSAID use after data were revised to "correctly apply enrollment criteria for cases and controls." The study was not powered to detect an effect for Vioxx based on duration of use.
Pfizer Macugen, C0X-2 Updates Expected At Nov. 30 Analyst Meeting
The meeting is expected to focus on Pfizer's pipeline, including the inhaled insulin Exubera and insomnia agent indiplon. Pfizer will likely discuss safety profile of its COX-2 inhibitors.